Chimerix Finds $11M

La Jolla-based Chimerix announced that it has raised a Series C round of funding for its biotechnology for the development of orally available medicines. The funding was led by Frazier Healthcare Ventures, with participation from existing investors Sanderling Ventures and Asset Management Company. Robert Overell of Frazier will join the company's board. The company said that the funding would be used for advancing their current therapeutic programs and to broaden the application of their proprietary technologies. More information »